The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu—a cancer-fighting drug with a name that belies its power—for treating HER2-positive early breast cancer in two critical moments: before surgery and after. This double approval, based on two major clinical trials, marks a significant expansion of hope for patients facing a disease that still catches nearly one in four off guard, even when it seems beaten.
HER2-positive early breast cancer is, by definition, among the most curable forms of the disease. Yet that one in four statistic haunts the conversation. Despite decades of progress, some patients who appear to be in remission experience recurrence—a devastating second blow that this new treatment aims to prevent. The FDA approval of Enhertu in both the neoadjuvant setting (before traditional surgery) and adjuvant setting (after initial therapy) reflects a fundamental shift: this drug is no longer peripheral to early breast cancer care. It's becoming foundational.
The evidence is striking. In the DESTINY-Breast11 trial, patients who received Enhertu before surgery, followed by standard triple therapy—a taxane, trastuzumab, and pertuzumab—achieved a pathologic complete response rate of 67.3 percent. Compare that to the 56.3 percent who received the older approach of dose-dense chemotherapy followed by triple therapy, and the advantage becomes clear. Those eleven percentage points represent hundreds of patients achieving deeper remissions before their surgeon ever enters the operating room.
The adjuvant data is equally compelling. In DESTINY-Breast05, patients with residual invasive disease who received Enhertu instead of the previous standard treatment, trastuzumab emtansine (T-DM1), saw their risk of invasive disease recurrence or death slashed by 53 percent. At the three-year mark, 92.4 percent of Enhertu-treated patients remained alive and free of invasive disease, compared with 83.7 percent in the comparison group. That eight-point difference is not abstract—it translates to real lives extended, real families spared the trauma of recurrence.
What makes this approval particularly meaningful is its timing within a patient's journey. For those diagnosed with stage II or III HER2-positive breast cancer, Enhertu can now be offered upfront, shrinking tumors before surgery and improving the likelihood of achieving complete pathologic response. For those who carry residual disease after initial treatment—a sobering reminder that the standard approach didn't work fully—Enhertu offers a second chance to prevent what once seemed inevitable.
Dave Fredrickson, executive vice president for AstraZeneca's oncology hematology business unit, described the approvals as expanding "the possibility of a cure to more patients for the first time in many years." That language matters. It's not about extending survival by a few months; it's about reaching toward cure in a disease where that word was once reserved for early cases caught by luck. The positioning of Enhertu as foundational—meaning it anchors treatment plans rather than serving as a backup—signals a genuine rethinking of how to approach this cancer from the start.
These approvals arrive for patients who have waited not for a miracle, but for science to catch up to the promise it had already begun to show. They represent the kind of incremental but meaningful progress that restores hope without ignoring the gravity of what's at stake.